Current Standard of Care and Symptom Management
At a Glance
Care for MSMO1 deficiency and GLS variants centers on prompt, individualized cataract care, lifelong eye monitoring, seizure treatment, and developmental therapies. Cholesterol and statin approaches are off-label, while GLS inhibitors remain limited to laboratory and animal research.
When managing an ultra-rare metabolic disorder, care is divided into two parts: standard surgical and neurological support, and experimental metabolic treatments. Because these conditions are so rare, there is no “rulebook,” but doctors follow established guidelines for managing the individual symptoms.
Evidence Level Guide:
- Established Practice: Cataract surgery, glaucoma surveillance, seizure management, physical/occupational therapy.
- Off-Label/Case Report: Oral statins/cholesterol and compounded topical creams for MSMO1.
- Preclinical: GLS inhibitors (CB-839) tested only in animal models.
Vision Care: Timing is Critical
The most urgent part of care is often managing the infantile cataracts. The lens must be clear for the brain to learn how to see. If the brain does not receive clear images during the first few months of life, it may never develop normal vision—a condition called amblyopia [1].
- Surgical Window: Surgery timing depends on whether the visual axis is obstructed, cataract density and laterality, retinal status, and the surgeon’s protocol. It requires prompt pediatric ophthalmology assessment and individualized timing [1][2].
- Post-Surgical Monitoring: Surgery is only the first step. Children need lifelong follow-up to check for glaucoma (high eye pressure), which is a common complication after infant eye surgery [3][4].
- Visual Correction: After surgery, your child will need immediate correction with aphakic contact lenses or glasses to focus light, followed by “patching” therapy to strengthen the eyes [5][6].
Metabolic Management for MSMO1 Deficiency
For children with MSMO1 deficiency, the goal in experimental care is to bypass the metabolic “roadblock”. These approaches are based entirely on small case reports or series with variable response, are considered off-label, and have no established benefit for cataracts or neurodevelopment.
- Combination Therapy: Case reports show use of a combination of oral cholesterol supplements and statins (like simvastatin) [7][8]. While statins are usually for high cholesterol, here they are used off-label to slow down the production of the “unfinished” sterols [7].
- Skin Support: Specialized topical cholesterol and statin creams applied directly to the skin have been described in reports to clear the red, scaly patches (psoriasiform dermatitis) [7][8]. Do not obtain or apply compounded treatments without the treating team’s oversight.
- Monitoring: Because these treatments are powerful, your doctor will regularly check liver enzymes and creatine kinase (CK) [8].
Managing Glutamate in GLS Variants
There is currently no approved drug that “fixes” the overactive GLS enzyme in humans, and no clinically validated GLS-directed therapy exists.
- Seizure Management: If your child has epilepsy, a pediatric neurologist will use standard anti-seizure medications tailored to the child’s specific seizure type [9][10].
- Experimental Research: Scientists have studied GLS inhibitors (like Telaglenastat/CB-839) in labs, finding they alleviated cataracts in zebrafish [10][11]. This is strictly preclinical evidence, not a demonstrated treatment outcome in children.
Surveillance: An Illustrative Example
A child with these symptoms needs a coordinated “home base”. Fixed intervals vary by patient; this is merely an example of what to expect:
- Ophthalmology: Frequent checks for eye pressure (glaucoma), visual acuity, and lens clarity [4].
- Metabolic Genetics: Sterol profiles, amino acids, growth, and liver function as dictated by therapy [7]. Repeat MRS is not routine unless a specialist has a specific indication.
- Neurology: EEG for seizure activity and developmental milestones [10].
- Early Intervention: Physical, occupational, and speech therapy for developmental support [7].
Common questions in this guide
How quickly should an infant with a cataract be evaluated?
What care is needed after infantile cataract surgery?
Are cholesterol supplements and statins proven for MSMO1 deficiency?
Can creams treat the skin changes linked to MSMO1 deficiency?
Is there a treatment to correct excess glutamate in GLS variants?
How are seizures and developmental difficulties managed in GLS-related disorders?
What monitoring should a child with these disorders receive?
Get notified when new evidence is published on infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Congenital Cataract Screening.
Rajavi Z, Sabbaghi H
Journal of ophthalmic & vision research 2016; (11(3)):310-2 doi:10.4103/2008-322X.188389.
PMID: 27621790 - 2
Postoperative amblyopia in children with congenital cataracts: a systematic review and meta-analysis.
Hailaiti A, Yu X, Yao K, Shentu X
Italian journal of pediatrics 2025; (51(1)):141 doi:10.1186/s13052-025-02010-x.
PMID: 40390126 - 3
Updates on managements of pediatric cataract.
Mohammadpour M, Shaabani A, Sahraian A, et al.
Journal of current ophthalmology 2019; (31(2)):118-126 doi:10.1016/j.joco.2018.11.005.
PMID: 31317088 - 4
Incidence and Risk Factors of Early-onset Glaucoma following Pediatric Cataract Surgery in Egyptian Children: One-year Study.
I Gawdat G, M Youssef M, M Bahgat N, et al.
Journal of current glaucoma practice 2017; (11(3)):80-85 doi:10.5005/jp-journals-10028-1229.
PMID: 29151681 - 5
Current management of infantile cataracts.
Lenhart PD, Lambert SR
Survey of ophthalmology 2022; (67(5)):1476-1505 doi:10.1016/j.survophthal.2022.03.005.
PMID: 35307324 - 6
Clinical Features and Outcomes of Congenital Cataract Surgery with Primary Intraocular Lens Implantation in a Tunisian Cohort.
Malek I, Sayadi J, Sammouda T, et al.
Journal of current ophthalmology 2022; (34(2)):187-193 doi:10.4103/joco.joco_273_21.
PMID: 36147275 - 7
MSMO1 deficiency: a potentially partially treatable, ultrarare neurodevelopmental disorder with psoriasiform dermatitis, alopecia and polydactyly.
Tkemaladze T, Bratland E, Bregvadze K, et al.
Clinical dysmorphology 2023; (32(3)):97-105 doi:10.1097/MCD.0000000000000461.
PMID: 37195326 - 8
New Homozygous Missense MSMO1 Mutation in Two Siblings with SC4MOL Deficiency Presenting with Psoriasiform Dermatitis.
Kalay Yildizhan I, Gökpınar İli E, Onoufriadis A, et al.
Cytogenetic and genome research 2020; (160(9)):523-530 doi:10.1159/000511126.
PMID: 33161406 - 9
Structure and enzymology of glutaminase S482C and H461L variants associated with excess brain glutamate and neurological disease.
Crane CS, McIssac TK, Milano SK, et al.
The Journal of biological chemistry 2026; (302(6)):113091 doi:10.1016/j.jbc.2026.113091.
PMID: 42055345 - 10
GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay.
Rumping L, Tessadori F, Pouwels PJW, et al.
Human molecular genetics 2019; (28(1)):96-104 doi:10.1093/hmg/ddy330.
PMID: 30239721 - 11
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Gregory MA, Nemkov T, Reisz JA, et al.
Experimental hematology 2018; (58()):52-58 doi:10.1016/j.exphem.2017.09.007.
PMID: 28947392
This page is for informational purposes only and does not constitute medical advice. It summarizes established, off-label, and experimental care for children with MSMO1 deficiency or GLS variants; pediatric specialists should guide treatment decisions.